Case File
efta-efta00625751DOJ Data Set 9OtherDS9 Document EFTA00625751
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00625751
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
To: "Jeffrey Epstein" <[email protected]>
Subject: Fw: Proposed SC investment framework - for discussion
Date: Sun, 14 Apr 2013 13:29:51 +0000
Importance: Normal
Please review below and let me know your opinion. Many thanks!
Original Message
From: Ramesh Venkataraman
To: David Stem
Subject: Proposed SC investment framework - for discussion
Sent: 13 Apr 2013 21:17
David,
Hope your trip to China is going well. Apologies that it has taken me a week to follow up on our discussions.
Have been swamped on a number of fronts including an unexpected (but hopefully positive) turn of events on
Poseidon — will brief you on your return from China.
Here is a proposed framework that I have developed for your review/comment. Let me have your thoughts
either via email or, if you prefer, we can wait until your return to discuss in person.
I.
Subject to confirmatory diligence (expected to take no more than 2-3 weeks) and final documentation, SC
will invest $5 million in July 2013 or as soon as AG receives the first RMB 1 mn from Chengdu. As discussed,
this $5 million amount will be the only funding commitment from SC to AG (and this should be documented and
minuted by AG for the avoidance of doubt/misconception). However, as discussed, we are fully committed to
assisting you/AG in future rounds of capital raising from other investors including tapping the Samena network.
2.
Our instrument will be structured as preference shares (zero coupon) convertible into common equity upon
a liquidity event (IPO, trade sale, partial divestment).
3.
Our instrument will presumably rank behind the Informa $16 mn loan note from 2010 (payable in 2020
with a 10% roll up coupon) and only be payable after that loan note principal and accrued interest are paid out.
We can refine our structure once we have access to the loan note docs and understand the draw down schedule
and payment obligations.
4.
The conversion ratio for our instrument into equity shares will be on the basis of a liquidity preference
table as follows:
A.
If a liquidity event happens before the next capital raising round or 18 months from the date of our
investment (whichever is earlier): our instrument earns a fixed IRR of 50%. The idea here is to give you and
the current management team disproportionate 'credit' for the liquidity event if it is achieved relatively quickly
after we invest. To explain by way of an illustration, if AG is sold in 12 months at an Enterprise Value (EV) of,
say, $50 mn then the payment waterfall is as follows:
a.
Informa - $16 mn plus accrued interest, say, $5mn = $21 mn
b.
SC - $7.5 mn (50% IRR for 12 months on $5 mn investment)
c.
Balance $21.5 mn to be split across the remaining common equity holders in proportion to their
shareholding %
B.
If a liquidity event happens after the next capital raising round or the 18 month anniversary of the date of
the SC investment:
Exit EV 'waterfall'
Samena % of exit proceeds
$m
EFTA00625751
0 to 100
50%
100 to 500
20%
500 plus
10%
The way to read this is as follows - `if the EV at exit is $50 mn, then Samena will get 50% of the amount over
that owed to Informa. If the Informa loan note principal + accrued interest repayment obligation is $24 mn, then
Samena gets $13 mn and the other common equity holders get $13 mn. If the EV at exit is $120 mn, then SC
gets $42 mn (50% of $76 mn plus 20% of $20 mn). If the exit is at a blockbuster EV of $500M, SC gets $118M
and the other equity holders collectively get $358 mn, with the balance $24 mn of course being payable to
Informa.
5.
Any new investor in a subsequent round (say in 2014) buys into the equity in a normal way, ie, the board
sets a pre-money valuation for the equity etc. The SC prefs do not get diluted — ie, the conversion framework
outlined above stays the same.
6.
Other terms can be worked out, eg, negative covenants, board seats, IPO secondary offering rights, etc. It
is also going to be critical to discuss how AG's bum rate can be reduced — ideally cut below $700K p.m., so our
investment plus the $6M of cash that AG has currently can last at least 18 months just in case of the inevitable
execution delays in Chengdu.
David, please treat this as a draft for discussion that we can refine over the next few days based on your feedback
to arrive at a mutually acceptable framework.
Best
Ramesh
EFTA00625752
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.